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Abstract: The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients
worldwide, presents an urgent need for effective treatments. To date, there are no therapies or
vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including
drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is
remdesivir, which is US Food and Drug Administration (FDA) approved for emergency use in adults
and children hospitalized with severe suspected or laboratory-confirmed COVID-19. Herein we
summarize the general features of SARS-CoV-2’s molecular and immune pathogenesis and discuss
available pharmacological strategies, based on our present understanding of SARS-CoV and Middle
East respiratory syndrome coronavirus (MERS-CoV) infections. Finally, we outline clinical trials
currently in progress to investigate the efficacy of potential therapies for COVID-19.
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1. Introduction
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has rapidly
spread worldwide and produced unprecedented social and economic harm. Coronavirus disease-19
(COVID-19) is an illness caused by this novel coronavirus and can present with symptoms ranging from
mild or minimal respiratory symptoms to acute respiratory distress syndrome (ARDS). During the last
twenty years, coronaviruses have caused three epidemics of lethal diseases: severe acute respiratory
syndrome (SARS), Middle East respiratory syndrome (MERS) and COVID-19. SARS-CoV-2 seems to be
less virulent than SARS-CoV or MERS-CoV with mortality rates of 3.4%, 9.6% and ~35%, respectively [1]
but appears to be more infectious.
This rapid spread of COVID-19 has generated intense research interest to find a cure or a vaccine.
However, there are no Food and Drug Administration (FDA)-approved drugs for the treatment
of COVID-19, although remdesivir, an investigational antiviral drug, is available through an FDA
emergency use authorization [2]. Several medicines with antiviral or immunomodulatory mechanisms
have been recommended as potential investigational therapies, many of which are currently being
studied in clinical trials. To date, therapies with proven benefit in certain groups include remdesivir,
dexamethasone and convalescent plasma [3–5]. This review describes the structure of SARS-CoV-2,
its molecular and immune pathogenesis and summarizes current knowledge about the potential
mechanisms for off-label agents widely used to treat COVID-19.
2. Virology of SARS-CoV-2
SARS-CoV-2 (about 120 nm in diameter) is an enveloped, positive-sense single-stranded RNA
(26–32 kb) virus that belongs to the genus Betacoronavirus of the family Coronaviridae in the Nidovirales
order. The subgroups of the family are alpha (α), beta (β), gamma (γ) and delta (δ) coronaviruses [6].
During the last two decades, several highly pathogenic human coronaviruses have emerged including
SARS-CoV in 2002–2003, MERS-CoV in 2012 [1] and SARS-CoV-2 in 2019.
Several phylogenetic analyses of the origin of the SARS-CoV-2 suggests bats are the most likely
animal reservoir. Full-genome evolutionary analysis suggests that SARS-CoV-2 is closely related to
BatCoV RaTG13 with 96.3% sequence similarity [7] and two SARS-like coronaviruses derived from
bats (bat-SL-CoVZC45 and bat-SL-CoVZXC21) with 88% similarity, compared to only 79% and 50%
similarity to SARS-CoV and MERS-CoV, respectively [8] (Figure 1). Transmission of SARS-CoV-2
from bats to humans is likely to have involved an intermediate host, as seen for SARS-CoV (palm
civets) and MERS-CoV (dromedary camels). Metagenomic sequencing suggests that Pangolins
could be the intermediate hosts due to the genome similarity of Pangolin-associated coronavirus to
SARS-CoV-2 (approximately 85.5–92.4%) [9]. A comprehensive synonymous codon usage (RSCU) bias
analysis suggests SARS-CoV-2 might be a recombinant between bat coronavirus and an unknown
coronavirus with the same codon usage bias as snake coronavirus [10]. Population genetic analysis
of 103 SARS-CoV-2 genomes by Tang et al. [11] indicated that this virus has evolved into two main
types, L and S types. The L type (~70%) is more prevalent than the S type (~30%), due to its higher
transmission and/or replication rates, although the S type is older in evolutionary terms [11].
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Figure 1. Coronavirus genomic organization. Coronaviruses are enveloped particles 100–160 nm in 
diameter with a 26–32 kb single stranded RNA (ssRNA) genome. Severe acute respiratory syndrome 
coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) share a common open reading frame 1 
(ORF1)a/b which encodes a polyprotein. The other ORFs are responsible for coding the four main 
structural proteins: spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins plus several 
accessory proteins. 
3. Coronavirus Entry and Replication 
All coronaviruses have specific genes downstream of the open reading frame 1 (ORF1) that 
encode for proteins necessary for viral replication and generation of the nucleocapsid and spike 
proteins [12]. SARS-CoV-2 has 14 ORFs encoding for 27 proteins. ORF1a/b and ORF1a are located at 
the 5′ end of the SARS-CoV-2 genome and code for the pp1ab and pp1a polyproteins, respectively. 
These polyproteins contain 15 non-structural proteins (NSP) including NSP1 to NSP10 and NSP 12 
to NSP 16. The 3′ end of the genome encodes four structural proteins including spike glycoprotein 
(S), envelope protein (E), matrix protein (M), nucleocapsid protein (N) and eight accessory proteins 
(3a, 3b, p6, 7a, 7b, 8b, 9b, and ORF14). Despite similarity in the overall amino acid composition of 
SARS-CoV-2 and SARS-CoV, remarkable amino acid differences have been identified [13]. 
The glycoprotein spikes located on the outer surface of coronaviruses work as multifunctional 
proteins contributing to host receptor binding, cellular tropism and pathogenesis [14]. The amino 
acid sequence of the SARS-CoV-2 S-protein is 76.47%, similar to that of SARS-CoV, leading to the 
same structural and electrostatic characteristics at the interaction interface [15]. The S-protein of 
SARS-CoV-2 resembles a mixture of bat SARS-CoV and an anonymous Beta-CoV [16], with the 3-D 
structure of the receptor binding domain (RBD) region maintaining similar van der Waals 
interactions [17]. 
Both SARS-CoV and SARS-CoV-2 use angiotensin converting enzyme II (ACE2) to enter human 
and bat cells [18]. The interaction between glutamine 493 in the RBD region of the SARS-CoV-2 spike 
Figure 1. Coronavirus genomic organization. Coronaviruses are enveloped particles 100–160 nm in
diameter with a 26–32 kb single stranded RNA (ssRNA) genome. Severe acute respiratory syndrome
coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) share a common open reading frame 1
(ORF1)a/b which encodes a polyprotein. The other ORFs are responsible for coding the four main
structural proteins: spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins plus several
accessory proteins.
3. Coronavirus Entry and Replication
All coronaviruses have specific genes downstream of the open reading frame 1 (ORF1) that encode
for pr tei s necessary for viral replication and generation of the nucleocapsid and spike proteins [12].
SARS-CoV-2 has 14 ORFs encoding for 27 proteins. ORF1a/b and ORF1a are located at the 5′ end of the
SARS-CoV-2 genome and code for the pp1ab and pp1a polyproteins, respectively. These polyproteins
contain 15 non-structural proteins (NSP) including NSP1 to NSP10 and NSP 12 to NSP 16. The 3′ end of
the genome encodes four structural proteins including spike glycoprotein (S), envelope protein (E), matrix
protein (M), nucleocapsid protein (N) and eight accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b, and ORF14).
Despite similarity in the overall amino acid composition of SARS-CoV-2 and SARS-CoV, remarkable
amino acid differences have been identified [13].
The glycoprotein spikes located on the outer surface of coronaviruses w rk as multifunctional
proteins c ntributing to host rec pto binding, cellular tropism and pathogenesis [14]. The amino acid
sequence of the SARS-CoV-2 S-protein is 76.47%, similar t that of SARS-CoV, leading to the same
structural and electrosta ic characteristics at the interaction interface [15]. T e S-protein of SARS-CoV-2
resembl s a mixture of bat SARS-CoV and a anonymou Bet -C V [16], with the 3-D structure of the
receptor binding domain (RBD) region maintaining similar van der Waals interactions [17].
Both SARS-CoV and SARS-CoV-2 use angiotensin converti g enzym II (ACE2) to enter human
and bat cells [18]. The interaction between glutamine 493 in the RBD region of the SARS-CoV-2 spike
protein and lysine 31 on the human ACE2 receptor plays an important role in viral binding and
entry [19]. Cryo-electron microscopy (Cryo-EM) structure analysis of the spikes shows that the binding
efficiency of the SARS-CoV-2 S protein to ACE2 is 10 to 20-fold higher than for SARS-CoV [20]. A single
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N501T mutation in the spike protein of SARS-CoV-2 significantly enhances the binding affinity for its
receptor, contributing to the high transmissibility of COVID-19 [19].
The spike protein of coronaviruses forms a trimer that generates a crown-like structure on
the envelope, giving this virus family its name (corona = crown) [14]. This large glycoprotein is
divided functionally into the S1 and S2 domains. The S1 domain (amino acids 15–680 in SARS-CoV)
is responsible for virus binding to its receptor on the target cell and comprises two sub-domains:
the N-terminal and the C-terminal of RBD which consists of 193 amino acids (318–510 in SARS-CoV).
The S2 domain of the spike protein (amino acids 681–1255 in SARS-CoV) participates in cell membrane
fusion [17,21]. Cellular proteases including human airway trypsin-like protease (HAT), transmembrane
protease serine 2 (TMPRSS2) and cathepsin trigger cleavage of the S protein trimer in SARS-CoV,
while furin makes the MERS-CoV S protein competent for fusion. TMPRSS2 is a serine protease localized
to the plasma membrane that is responsible for proteolysis of the S protein after receptor-binding [22].
However, the mechanism of enhanced membrane invagination seen during SARS-CoV-2 endocytosis
has not been identified [23].
The initial step during SARS-CoV-2 infection is the binding of S to its host receptors, inducing
uptake of virus particles by endocytosis and fusion between host and viral membranes [18].
Following membrane fusion and viral entrance, viral genomic RNA is released into the cytoplasm of
infected cells. This uncoated RNA acts as a template for translation of the two polyproteins, pp1a and
pp1ab. The nsp3 and nsp5 encodes two protease enzymes named papain-like proteases (PLpro) and
chymotrypsin-like protease (3CLpro) which cleavage between pp1a and pp1ab to form nsps1–11 and
1–16, respectively [24]. A large number of non-structural proteins make the replication–transcription
complex (RTC) in double-membrane vesicles. The accessory and structural proteins are generated by
translation of a nested set of subgenomic RNAs synthesized by the RTC. Moreover, a negative strand
RNA template is transcribed and forms a complex with intermediate products for transcription of
positive-sense mRNAs including the progeny genome and subgenomic RNA, mainly mediated by
RNA-dependent RNA polymerases (RdRp) [25]. In the infected cell, newly synthesized viral genomic
RNA, the structural nucleocapsid and envelope glycoproteins are assembled into viral particles in the
endoplasmic reticulum (ER) and Golgi apparatus. In the final step, budding of the viral particles occur
through fusion of the plasma membrane and virion-containing vesicles, leading to release of newly
formed virions [23].
4. Pathogenesis of COVID-19
Although the immunopathogenesis of COVID-19 is not well understood, its clinical symptoms
and signs vary from fever and fatigue to severe respiratory complications and multi-organ failure [26].
Understanding the immunopathogenesis of COVID-19 and the differences between affected individuals
is essential for designing therapies and decreasing mortality. One approach is to study similar viruses
such as SARS-CoV and MERS-CoV and learn from previously described host–pathogen interactions [27].
As discussed, SARS-CoV-2 employs ACE2 as the host cell receptor. ACE2 is highly expressed on
many different cell types in a variety of human organs, including lung alveolar epithelial cells and small
intestinal epithelial cells, both of which are considered potential SARS-CoV-2 routes of transmission.
Overall, ACE2 is expressed widely in the main target organs of SARS-CoV-2, as well as organs that
play less important or even unknown roles in COVID-19 pathophysiology [28]. It has been reported
that SARS-CoV also infects immune cells such as T lymphocytes, monocytes and macrophages [29],
but it remains poorly defined as to what extent SARS-CoV-2 also targets these cells. A number of
studies are exploring the immune response to the SARS-CoV-2 [30], with most suggesting that the
immune response is disturbed due to aberrant activation of monocytes/macrophages [31], elevation of
pro-inflammatory cytokines [32], depletion of lymphocytes [33] and deployment of large numbers of
neutrophils [34], but the complex mechanisms involved are still not well understood.
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5. The Innate Immune Response to SARS-CoV-2 and Virus-Induced Degradation of RNA Sensors
Similarly to other viral infections, the expression of type I interferons (TI IFN), such as
interferon (IFN)-α and IFN-β, determine the innate immune response to SARS-CoV-2 infection [35].
Pathogen associated molecular patterns (PAMPs) such as viral RNA are sensed by pattern recognition
receptors (PRRs) on innate immune cells including antigen presenting cells (APCs), resulting in their
activation [36]. Endosomal PRRs including Toll-like receptors (TLR-) 3, 7/8 and 9 are responsible for
detection of SARS-CoV-2 [24]. These TLRs are mainly expressed in macrophages and dendritic cells,
which are involved in innate immunity [37]. Activation of the TLRs leads to nuclear translocation of NFκB
and IFN regulatory factor 3 (IRF3) transcription factors resulting in TI IFN overexpression and the release
of pro-inflammatory cytokines (interleukin (IL)-1, IL-6 and Tumor necrosis factor TNF-α), which have
been reported to be overexpressed significantly in SARS-CoV-2 infection in association with “cytokine
storm” [37,38]. TI IFNs and these other cytokines also amplify their own expression [39], priming the
adaptive immune response or pathogen clearance. However, the inflammatory status can be excessive
and is one of the major determinants of COVID-19 disease [27].
In addition to TLRs, several other receptors including RIG-I-like receptors (RLRs) [27],
C-type lectin-like receptors (CLRs) [40], NOD-like receptor (NLR) especially NLRP3 inflammasome [41],
and free molecule receptors such as STING, cGAS, IFI16 and DAI can be involved in the recognition
of viruses and in mediating immune response-related signaling pathways [42]. RLRs are comprised
of the H family members RIG-I (DDX58), MDA5 (IFIH), and LGP2 which recognize the genomic
structure of RNA viruses such as SARS-CoV-2 [27]. NLRs are a subclass of PRRs which are comprised
of a conserved NOD structure and classified into three main categories according to their functions:
inflammasome (NLRP1, NLRP3, NLRP6, NLRC4, NLRC5W, and AY2); embryo regenerative and
regulatory NLRs [25,41]. CLRs are soluble PRRs mostly expressed in myeloid cells responsible for
phagocytosis, maturation of dendritic cells (DCs) and chemotaxis and have been proposed to be
associated in SARS-CoV-2 immunopathogenesis [40,43].
Like other viral infections, the SARS-CoV-2 antigens are processed by specific antigen presenting
cells (APCs) including macrophages and dendritic cells [44]. The antigens are then presented by
major histocompatibility complexes (MHC) or human leukocyte antigens (HLA) to specific cytotoxic
T lymphocytes (CTLs) [45]. It is thought that SARS-CoV-2 relies on MHC I, like SARS-CoV and
MERS-CoV, with minimal contribution by MHC II [46]. HLA polymorphisms have been correlated
with an altered risk of SARS-CoV and MERS-CoV [47], so it is predicted that polymorphisms in HLA-A,
HLA-B, HLA-DR B1, HLA-Cw and HLA-DQB1 could also exert an effect on the immunopathogenesis
of SARS-CoV-2 [47].
However, like SARS-CoV and MERS-CoV, SARS-CoV-2 is capable of escaping the immune
response [48]. For example, SARS-CoV can successfully shift ubiquitination and enhance degradation
of RIG-I/MDA5 RNA sensors, TLR3, TLR7 and TLR8 [49]. Furthermore, SARS-CoV and possibly
SARS-CoV-2 can suppress innate immune responses without triggering the anti-viral response
machinery, by counteracting NFκB and TI IFN signaling [50]. Moreover, protective immunity against
SARS-CoV-2 has not been reported and the virus is capable of immune escape and proliferation in
infected organs [36].
6. Regulation of Adaptive Immune Response in SARS-CoV-2 Infection
6.1. T-Cell Mediated Immune Responses Against SARS-CoV-2 and Mechanisms of Immune Escape
T lymphocytes play a crucial role in the anti-viral immune response to coronaviruses [32]. Cluster of
differentiation CD4+ and CD8+ T cells maintain the balance between the immune response against these
pathogens and immune tolerance [51,52]. Antibody-producing B cells are activated by CD4+ T cells,
while CD8+ T cells are cytotoxic to virus-infected cells [53]. During SARS-CoV infection, the majority
(approximately 80%) of inflammatory cells infiltrating the lungs of affected individuals are CD8+ T cells [54]
and T cells can survive in infected tissues [55]. In contrast, CD4+ T cells are more susceptible than CD8+
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cells to infection by MERS-CoV and SARS-CoV [56]. During SARS-CoV-2 infection, a reduction in the
number and quality of CD4+ T cells could be associated with decreased activation of B lymphocytes,
with reduced levels of virus-specific neutralizing antibodies and pro-inflammatory cytokines (including
IL-1β, IL-6 and TNF-α), leading to defective clearance of virus from infected organs [56]. Cooperating with
innate immune cells, helper T cells are involved in producing major pro-inflammatory cytokines via NF-kB
activation, which is responsible for initiating the production of pro-inflammatory cytokines involved in
the cytokine storm [24]. IL-17 produced by Th17 cells mediates the activation of monocytes/macrophages,
dendritic cells (DCs) and neutrophils and enhances the production of cytokines (IL-1, LL-6, IL-8, IL-21,
TNF-α, and Monocyte chemoattractant protein-1 (MCP-1)) from these cells [30]. The possible role of IL-17
and related altered cytokines are highlighted in SARS-CoV-2 infection [57].
One of the important methods that SARS-CoV-2 may use to evade T cell-mediated immune
responses is the induction of apoptosis, similar to previous reports in MERS-CoV and SARS-CoV,
by enhancing the binding of T-cells to B-cell lymphoma-extra-large (Bcl-xL) molecules [58].
Although this might result in T-cell depletion, recent findings suggest that the T cell response
to structural proteins of coronaviruses (including the S, M and N proteins) persists, providing effective
and long-term T-cell responses against COVID-19, which conveys promise for developing vaccines [58].
6.2. Humoral Immune and Antibody Responses to Coronavirus Infection
All subtypes of B lymphocytes are involved in the humoral immune response against coronavirus
infections [59]. Several antibodies which have been isolated and designated from MERS-CoV and SARS-CoV
infected patients are MERS-GD27, CDC-A2, CDC-C2, MCA1, CSC-C5, CDC-A10, and MERS-GD33.
We could expect that structurally similar antibodies would be isolated from SARS-CoV-2 patients [60].
The RBD of the SARS-CoV-2 S protein has been identified as an immunodominant and highly specific
target for antibodies in affected patients [61]. Since the RBD of the S protein is poorly conserved among
SARS-CoVs and other coronaviruses it is a promising antigen for detecting coronavirus specific antibodies,
as demonstrated by Premkumar et al. using a large panel of human sera [62,63]. Zost et al. demonstrated
that several human monoclonal antibodies (mAbs) targeting the S glycoprotein, including COV-2196 and
COV-2130, showed potential neutralizing activity and fully blocked the RBD from interacting with ACE2 [64].
Similarly, epitope mapping by Liu et al. identified a short list of 19 antibodies, equally divided between
those targeting the RBD or N-terminal domains, confirming that both are immunogenic [65].
The complement system is an innate immune compartment able to recognize and destroy pathogens
that works tightly with the humoral arm of immunity [66]. Viral proteins can mimic host proteins that
regulate the complement system, helping the virus to evade immune recognition [67]. C3a and C5a are
responsible for the inflammatory response activation of innate immune cells. Thus, inhibiting C3a and
C5a during infection with MERS-CoV, SARS-CoV or SARS-CoV-2 could be introduced as promising
targets to treat severe lung disease [68].
6.3. Cytokine Responses Across COVID-19; the Significance of IL-6 in Cytokine Release Syndrome (CRS)
Although several management strategies are evolving for COVID-19, severe disease results in the
ARDS associated with a cytokine release syndrome (CRS). CRS is caused by vast numbers of immune
cells producing pro-inflammatory cytokines in a positive feedback loop [69] and is one of the key
elements contributing to the mortality and morbidity of COVID-19 [70].
CRS is not specific to SARS-CoV-2 infection and has been demonstrated for MERS-CoV and
SARS-CoV, as well as for influenza A subtypes H5N1 and H7N9 [71]. The hallmarks of CRS are elevated
serum concentrations of pro-inflammatory cytokines including interleukin-6 (IL-6) and C-reactive
protein (CRP) [72]. A meta-analysis of nine different studies demonstrated significantly higher
IL-6 levels in people with severe COVID-19 disease than with non-severe disease (mean difference:
38.6 pg/mL, 95% CI: 24.3–52.9 pg/mL) and was associated with excess mortality [73].
Binding of SARS-CoV-2 to alveolar epithelial cells activates the immune system, leading to
secretion of a large number of cytokines, including IL-6 [74]. IL-6 is an important pro-inflammatory
Int. J. Mol. Sci. 2020, 21, 5559 7 of 34
and multifunctional cytokine involved in acute inflammation, metabolism, and autoimmune cell
differentiation [75]. IL-6 binds to soluble forms of IL-6 receptor (sIL-6R) and forms a complex with
gp130 dimers on the cell surface, activating the Janus kinase-signal transducer and activator of
transcription 3 (JAK-STAT3) signaling and inducing CRS [74]. Subsequently, vascular endothelial
growth factor (VEGF), MCP-1, IL-8, and more IL-6 are secreted, while E-cadherin is downregulated on
endothelial cells [76]. The reduction of E-cadherin and VEGF overexpression give rise to increased
vascular permeability [77]. IL-6 activates B cells, enhances the expansion and proliferation of T cells,
regulates CTL activity, promotes Th17 cell differentiation and inhibits the activation of regulatory
T cells (Tregs) [78]. Tocilizumab is a recombinant humanized monoclonal antibody against human
IL-6R [79,80]. It has been approved for the treatment of rheumatoid arthritis and systemic juvenile
idiopathic arthritis and there is increasing evidence it may be useful for COVID-19 disease [81–83].
Clinical analysis of COVID-19 patients admitted to a hospital in Wuhan, China reported that patients
showed elevated plasma concentrations of other cytokines including TNF-α, IL-7, IL1β, INFγ, IL1RA and
MIP1A/B. Moreover, cytokine levels were higher in patients admitted to the intensive care unit (ICU) [84].
Tumor necrosis factor-α (TNF-α) is an inflammatory cytokine secreted by activated monocyte/macrophages
as part of innate immune system and is directly correlated with COVID-19 disease severity (R = −0.322,
p < 0.001) [85]. Although targeting TNF-α is rational and appealing, the clinical efficacy of anti-TNF
antibodies (e.g., adalimumab) for SARS-CoV-2 infected patients needs further investigation [86].
7. COVID-19 and Comorbidities
The clinical presentations of COVID-19 are heterogeneous, so identifying comorbidities associated
with COVID-19 is important for several reasons. First, when treating patients, it allows health care
providers to adjust and select the best treatment option for vulnerable patients, reducing the risk of
side effects due to polypharmacy or drug–drug interactions. Second, it identifies people at higher
risk, assisting governments to stratify public health policies and guidelines to allow easing of social
distancing restrictions, while protecting the vulnerables. Finally, determining which comorbidities are
most associated with poor COVID-19 outcomes will help researchers to understand the pathophysiology
of SARS-CoV-2 infection and its interactions with underlying chronic diseases.
Early clinical experience suggested that the elderly and people of any age with serious underlying
medical conditions are at a greater risk of severe illness from COVID-19 [87]. Consistent with this,
previous studies showed the presence of comorbidities conferred a 3–4 fold increased risk of developing
acute respiratory distress syndrome in patients with SARS-CoV [88] and MERS-CoV infections [89].
For COVID-19, medical conditions that put people at increased risk of severe disease include: uncontrolled
diabetes; hypertension; lung, liver, and kidney disease; cancer; smoking; solid organ transplant; pregnancy;
thalassemia; asthma; neurologic conditions, such as dementia; pulmonary fibrosis (having damaged or
scarred lung tissues); obesity and long term steroid therapy [90,91]. A systematic review and meta-analysis
of 1576 patients with COVID-19 showed that hypertension (21.1%) and diabetes (9.7%) were the most
prevalent comorbidities, followed by cardiovascular disease (8.4%) and respiratory disease (1.5%) [92].
This reflects international studies, which show that comorbidities associated with poor outcomes in
COVID-19 include hypertension (20–30%), diabetes (10–20%), cardiovascular disease (8–12%), chronic
obstructive pulmonary disease (COPD) (1.5–7.5%), chronic kidney diseases (1–3%), cerebrovascular
disease (1.5–3%), co-infection with human immunodeficiency virus (HIV) or hepatitis B virus (1–2%),
malignancy (1–3.5%), respiratory illnesses (1.4%), renal disorders (0.5–1.5%) and immunodeficiencies
(0.01%) [93–98]. The most common comorbidity varied among the seven countries reviewed, as follows:
China (hypertension 39.5%), South Korea (cardiovascular disease 25.6%), Italy (hypertension 35.9%),
USA (hypertension 38.9%), Mexico, (other 42.3%), UK (hypertension 27.8%), Iran (diabetes 35.0%); diabetes
was the second most common comorbidity in five of them [93]. Evaluating the mechanisms underlying
the associations of severe COVID-19 disease with hypertension, diabetes and respiratory diseases is crucial
for the management of high-risk patients and for developing policies and guidelines to reduce future
risk of severe COVID-19 disease. Finally, strong precaution should be considered when managing and
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treating COVID-19 patients with preexisting cardiovascular risk factors, especially high blood pressure
and diabetes, while patients with uncontrolled hypertension should be informed about their increased
risk and advised to take appropriate preventative measures.
8. Available Treatment Options for COVID-19
An array of disease modifying drugs have been proposed for the specific treatment of COVID-19
disease and will be discussed below. The classification of drugs and the effective doses are listed in
Table 1 while their mechanism of action is illustrated in Figure 2.
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Figure 2. The life cycle of SARS-CoV 2 and potential mechanisms of action of drugs. The virus lifecycle
starts when the S protein binds to its cellular receptor angiotensin converti g enzyme II (ACE2).
Following a conformation change in the S protein, the viral envelope fuses with the cell membrane.
After endocytosis, the RNA of SARS-CoV-2 is released to the cytoplasm. Genomic RNA, which is
positive sense, is translated into the viral polyproteins pp1a and 1ab. The polymerase produces a series
of subgenomic mRNAs and translates the relevant viral proteins. In the endoplasmic reticulum (ER)
and Golgi, viral proteins and genome RNA are assembled into virions and transported via vesicles
and released out of the cell. ERGIC (ER–Golgi intermediate compartment). Site of action for each
therapeutic candidate is shown with red cross.
8.1. Antivirals
8.1.1. Remdesivir
Remdesivir (RDV) was originally developed as a treatment for Ebola and Marburg virus infection
and is a promising candi ate for treatment of COVID19. RDV is an adenosi e nucleotide analogue
with broad-spectrum antiviral activity against RNA viruses i cluding Filoviridae, Paramyxoviridae,
Pneumoviridae, and Coronaviridae. It ac s as an inhibito of RdRps and inhib ts virus replication
through premature termination of RNA transcription as it incorporates into nascent viral RNA
chains [99]. Antiviral activity of RDV against coronaviruses including SARS-CoV and MERS-CoV
was described in 2017 [100]. Recently, an in vitro study on Vero E6 cells has shown that remdesivir
at low-micromolar concentrations blocks SARS-CoV-2 infection with high selectivity (half-maximal
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effective concentration (EC50), 0.77 µM; half-cytotoxic concentration (CC50) > 100 µM; SI > 129.87) [101].
Interestingly, remdesivir demonstrated promising results in treatment of the first patient diagnosed with
COVID-19 in the United States [102]. In order to further investigate the efficacy and safety of this drug,
four clinical trials in severe and mild/moderate respiratory infections by SARS-CoV-2 in the United States
and two in China have been commenced [103]. The first randomized controlled clinical trial of
remdesivir in the United States, known as the Adaptive COVID-19 Treatment Trial, enrolled 1063 patients
and showed that patients who received remdesivir recovered faster, with a median time of 11 rather than
15 days (p < 0.001). There was also a non-significant trend towards reduced mortality (8.0% in remdesivir
arm vs 11.6% for the placebo arm, p = 0.059) [104]. In another cohort of 53 patients hospitalized
for severe COVID-19 in the United States, Europe, Canada or Japan a 10-day course of remdesivir
resulted in clinical improvement in 36 patients (68%) [105]. Another randomized, double-blind,
placebo-controlled, multicenter trial of remdesivir in 237 laboratory-confirmed SARS-CoV-2 infected
patients, from ten hospitals in China (NCT04257656), revealed that time to clinical improvement was
not associated with the use of remdesivir; adverse events were reported in 66% of patients [106].
On May 1st the emergency use of remdesivir for adults and children hospitalized with severe suspected
or laboratory-confirmed COVID-19 was approved by the US FDA [4].
8.1.2. Lopinavir/Ritonavir
Lopinavir/Ritonavir (LPV/r) is a coformulation of two structurally related protease inhibitor
antiretroviral agents primarily used for treatment of HIV-1 infection in adults and children over 2 years
of age. LPV/r reduces the replication of SARS-CoV and MERS-CoV in vitro [107,108] by inhibiting
viral proteases including 3CLpro or PLpro [108]. Ritonavir is used in combination with Lopinavir to
increase LPV half-life by inhibiting Cytochrome P450 3A4 (CYP3A4) [109]. A study of six patients
with confirmed COVID-19 infection in Korea and China showed a significant decrease in SARS-CoV-2
viral load and clinical improvement after administration of LPV/r [110,111]. However, concomitant
drug therapies, variation in starting time of therapy, different levels of illness severity, and the
lack of a control group reinforces the need for caution when interpreting such results [80,110,111].
In another study in Singapore the efficacy of LPV/r was evaluated on five patients with COVID-19
who required supplemental oxygen. Three of them improved within 3 days, while two experienced
progressive respiratory failure. [112]. On the other hand, in a retrospective cohort study among
29 hospitalized patients who received LPV/r and were discharged, no differences in viral shedding
duration was noted [113]. Similarly, Cao et al. reported a clinical trial including 199 patients with
SARS-CoV-2 infection, which showed that LPV/r was not associated with clinical improvement [114].
However, the low efficacy of LPV/r in this study might be attributed to the advanced pneumonia in
treated patients coupled with a lack of knowledge about the exact concentrations required to inhibit viral
replication [115]. So far 10 ongoing clinical trials have been registered from China, Korea, Thailand and
Hong Kong to evaluate efficacy of LPV/r for the treatment of COVID-19, either alone or in combination
with other antivirals including ribavirin, interferon beta-1b or Chinese traditional medicine [103]. It is
important to note that LPV/r has significant drug interactions including the risk of cardiac arrhythmia
due to QT- prolongation [116]. Cao et al. documented multiple side effects of LPV/r including
gastrointestinal adverse events (i.e., anorexia, nausea, abdominal discomfort, or diarrhea) as well as
acute gastritis, hepatic injury risk, pancreatitis, more severe cutaneous eruptions, and QT prolongation,
and the potential for multiple drug interactions [114]. The European Society of Intensive Care Medicine
(ESICM) and the Society of Critical Care Medicine (SCCM) have recommended against the routine use
of LPV/r in critically ill COVID-19 patients [117]. The National Institutes of Health (NIH) guidelines
recommend against the use of Lopinavir/ritonavir as a clinical benefit has not been demonstrated in
patients with COVID-19, due to unfavorable pharmacodynamics and a lack of clinical trials [2].
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8.1.3. Favipiravir
Favipiravir (FPV) is a guanine nucleic acid analogue approved for the treatment of resistant
strains of influenza [118]. Intracellular phosphoribosylation of favipiravir generates the active form
favipiravir-RTP (favipiravir ribofuranosyl-5B-triphosphate) which is a substrate for the RNA-dependent
RNA polymerase of RNA viruses and inhibits polymerase activity [118]. Favipiravir suppresses
the replication of flavi-, alpha-, filo-, bunya-, arena-, noro-, and of other RNA viruses [119].
Therefore, favipiravir may also have activity against SARS-CoV-2. The use of favipiravir for COVID-19
has been reported from limited clinical experiences. An open-label study in China compared the
effects of favipiravir plus interferon-α with LPV/r plus interferon-α for the treatment of COVID-19.
Favipiravir was associated with more rapid viral clearance, better improvement in chest imaging
results and less adverse effects [120]. Based on these results favipiravir was approved as the first
anti-COVID-19 drug in China [121]. Another randomized clinical trial compared the effect of favipiravir
and arbidolol in COVID-19 patients but demonstrated no difference in clinical recovery rate at day 7.
However, favipiravir significantly shortened the latency to relief from pyrexia and cough [122].
An ongoing clinical trial (NCT04303299) is investigating the efficacy, performance and safety of
favipiravir in combination with oseltamivir and chloroquine among 80 participants with COVID-19
in Rajavithi Hospital in Thailand; results will be released in November 2020 [123]. There is less
preclinical support for favipiravir to treat COVID-19 compared with remdesivir, due to its higher
EC50 (61.88 µM) compared to remdesevir (0.77 µM) [101,124]. Favipiravir is well tolerated in healthy
volunteers, however caution is required as it is teratogenic [119].
8.1.4. Ribavirin
Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a synthetic guanosine analogue
with broad-spectrum activity against several RNA and DNA viruses [125]. It was first approved
in 1972 and has been used as a therapeutic agent against respiratory syncytial virus, Lassa fever
virus, influenza A and B and in combination with interferon-α for hepatitis C [126]. Ribavirin has
multiple mechanisms of action-including interference with RNA capping, inhibition of polymerases,
introducing random mutations, suppression of natural guanosine generation by inhibition of inosine
monophosphate dehydrogenase and immunomodulatory effects by enhancing the T cell response [127].
The in vitro anti SARS-CoV activity reported for ribavirin differs widely depending on the cell lines
used for the antiviral assays. It is possible that ribavirin may be more effective when co-administrated
with IFN as this combination inhibited replication of SARS-CoV in five different cell types of animal
or human origin, at considerably lower concentrations than with either single treatment alone [128].
Similarly, the combination of IFN-α2b and ribavirin in vitro decreased the inhibitory concentration
against MERS-CoV to levels that are likely achievable in humans [129]. In terms of SARS-CoV-2,
in vitro studies revealed that high concentrations of ribavirin (EC50 of 109.5 µM) are required to reduce
the viral infection and ribavirin is 100 times less potent than remdesivir [101]. Administration of high
doses of ribavirin in SARS trials was associated with serious adverse reactions including haemolytic
anaemia, electrolyte disturbances and significant teratogenicity. [88,130,131]. Given its considerable
adverse effect profile, toxicity and the lack of in vitro data evaluating the efficacy of this compound,
the administration of ribavirin for the treatment of COVID-19 is not recommended. An ongoing trial in
China (ChiCTR2000029387) is evaluating the efficacy and safety of ribavirin and LPV/r in combination
with interferon alpha-1b for SARS-CoV-2 infection [132].
8.1.5. Arbidol Hydrochloride (Umifenovir)
Arbidol (ARB; ethyl-6-bromo-4-[(dimethylamino) methyl]-5-hydroxy-1-methyl-2-[(phenylthio)
methyl]-indole-3-carboxylate hydrochloride monohydrate), an indole derivative, is a broad-spectrum
antiviral against various enveloped and non-enveloped viruses and is widely used in Russia and
China [133]. Arbidol displays antiviral activity in vitro and/or in vivo against influenza viruses A, B and
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C, adenovirus, respiratory syncytial virus, SARS-CoV, parainfluenza type 5, poliovirus, rhinovirus
14, coxsackievirus B5, hantavirus, Chikungunya virus, hepatitis B virus (HBV) and hepatitis C virus
(HCV) [134]. The anti-viral mechanism of arbidol is thought to relate to inhibition of viral fusion
with target cell membranes and with the membranes of endosomes and consequently blockage of
virus entry [133]. For influenza A and B viruses it targets hemagglutinin (HA), the major glycoprotein
on the surface of the virion, thereby preventing infection [135]. For SARS-CoV, studies have shown
direct antiviral effects of arbidol and arbidol mesylate in vitro, with arbidol mesylate reducing the
reproduction of SARS-CoV five times more effectively than arbidol [136]. In China, limited clinical
experience with arbidol for COVID-19 treatment has been described. In one study from Wuhan in
67 hospitalized patients with confirmed SARS-CoV-2 infection, 36 (53.7%) received arbidol treatment
for a median duration of 9 days and demonstrated lower mortality rates (0% (0/36) vs. 16% (5/31)) and
higher discharge rates (33% (12/36) vs. 19% (6/31)) compared with patients who did not receive this
drug [137]. In a prospective, randomized, controlled, open-label multicenter trial investigating the
efficacy of favipiravir compared with arbidol in the treatment of COVID-19 patients, the clinical recovery
rate at day 7 did not differ between the favipiravir and arbidol groups [122]. Currently, multiple clinical
trials are investigating the efficacy of arbidol on COVID-19 patients in China and USA (NCT04260594,
NCT04255017). Four clinical trials are comparing arbidol with oseltamivir, LPV/r and carrimycin for
COVID-19 [123].
8.1.6. Camostat Mesylate (FoipanTM)
Camostat mesylate (N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate)
is a synthetic serine protease inhibitor used for the treatment of chronic pancreatitis, dystrophic
epidermolysis, oral squamous cell carcinoma and exocrine pancreatic enzyme inhibition [138].
Camostat mesylate was developed in Japan in the 1980s but very little data from outside Japan
is available. Some coronaviruses (SARS-CoV, MERS-CoV) and influenza virus activate their envelope
glycoproteins by employing host cell proteases [139]. Membrane fusion and host cell entry of SARS-CoV
is mediated by spike protein cleavage and activation which requires TMPRSS2, an airway and alveolar
cell serine protease [140]. Zhou et al. demonstrated that serine proteases cause the spread of SARS-CoV
and camostat effectively prevents this step, suggesting it may be an option for treating SARS and
potentially MERS [141]. Another study demonstrated that camostat partially blocked SARS-CoV
and human coronavirus NL63 (HCoV-NL63) infection in HeLa cells expressing the ACE2 receptor
and TMPRSS2 [142]. Additionally, the effect of camostat mesylate in blocking SARS-CoV-2 infection
of human lung Calu-3 cells has been demonstrated [143]. A double-blind randomized controlled
clinical trial is evaluating the efficacy of camostat mesylate for treatment of COVID-19 (NCT04353284),
but more studies are needed to clarify whether adequate concentrations for suppressing the virus can
be attained in a patient’s lung.
8.1.7. Nafamostat Mesylate
Nafamostat mesylate (6-amidino-2-naphthyl p guanidinobenzoate dimethanesulfonate) is a
synthetic serine protease inhibitor available in Japan since 1986 that has been approved for the
treatment of inflammatory-related diseases such as pancreatitis [144,145]. Nafamostat is a potent
inhibitor of S-mediated membrane fusion of MERS-CoV and blocks MERS-CoV infection in vitro [22].
The anti MERS-CoV activity of nafamostat is through inhibition of the host protease TMPRSS2, which is
responsible for the proteolysis of the S protein after the receptor-binding stage [22]. Recently a study
in lung cell culture tested the inhibitory effect of gabexate mesylate, nafamostat mesylate and camostat
mesylate on SARS-CoV-2 infection and demonstrated that nafamostat mesylate inhibited S-mediated
entry of SARS-CoV-2 into host cells 15 times more effectively that camostat mesylate, with an
EC50 in the low nanomolar range [146]. In another study, nafamostat was tested in vitro against a
clinical SARS-CoV-2 isolate and was shown to have antiviral activity, with an EC50 of 22.50µM [101].
An advantage of targeting host proteases instead of viral protein inhibitors is that it avoids treatment
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failure due to mutations of the target. Despite these promising in vitro data, the efficacy of nafamostat
as a COVID-19 treatment needs to be tested in clinical trials.
8.2. Anti-Parasites
8.2.1. Chloroquine/Hydroxychloroquine
Chloroquine (N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) has long been used
to prevent and treat malaria. It has also been tested in chronic viral diseases and has shown antiviral
activity against RNA and DNA viruses including HIV, influenza A and B viruses, influenza A H5N1
virus, HCV, rabies virus, hepatitis A virus, poliovirus, Chikungunya virus, Lassa virus, Dengue virus,
Hendra and Nipah viruses, Crimean–Congo hemorrhagic fever virus, Zika virus and Ebola virus,
as well as HBV and herpes simplex virus [147]. Sometimes the antiviral activities of chloroquine
described in vitro have been confirmed in virus-infected patients, however, the results have not always
been reproduced in clinical trials.
Chloroquine possesses different mechanisms of action depending on the pathogen studied.
In vitro studies on SARS-CoV showed that chloroquine can interfere with glycosylation of ACE2,
in Vero cells [148]. Since SARS-CoV-2 uses a similar receptor, it is expected that chloroquine may
prevent SARS-CoV-2 attachment to target cells by the same mechanism. Moreover, chloroquine
can induce autophagosome formation resulting in spike protein degradation by changing the pH
of lysosomes and inhibition of cathepsins. Furthermore, chloroquine interferes with viral assembly,
budding and proteolytic processing of the M protein through inhibition of Mitogen-activated protein
kinases (MAPK) [149].
Previous studies have reported the potential use of chloroquine for treatment of SARS-CoV [150].
The potent efficacy of remdesivir and chloroquine were evaluated in Vero E6; chloroquine was effective
in controlling SARS-CoV-2 infection in vitro with an EC50 at 48 h of 1.13 µM [101], comparable with
previous in vitro findings against SARS-CoV and MERS-CoV [151]. Besides the antiviral activity of
chloroquine, it has immune modulatory functions by inhibition of TNF-α and IL-6 production and
secretion. Upon oral administration of chloroquine, it is widely distributed systemically in the body,
reaching the lung [101]. There is safety concern in administration of chloroquine due to the risk of
macular retinopathy and cardiomyopathy [152,153]. Despite the in vitro efficiency of chloroquine,
the clinical outcomes are uncertain.
Hydroxychloroquine sulfate, a derivative form of chloroquine, was first synthesized in 1946 by
introducing a hydroxyl group into chloroquine. It has two to three times less toxicity in animals compared
to chloroquine [154]. Hydroxychloroquine likely has the same mechanism of action on viruses as that of
chloroquine and acts as a weak base compound, changing the pH of endosomes/lysosomes [155].
There is limited published evidence supporting the activity of hydroxychloroquine against
coronaviruses. An in vitro study in Vero cells showed that the chloroquine was approximately 5-fold
more potent (EC50 of 6.5 ± 3.2 µM) than that of hydroxychloroquine (EC50 of 34 ± 5 µM) against
SARS-CoV [156]. Conversely, the potency of hydroxychloroquine in Vero cells infected with SARS-CoV-2
(EC50 of 0.72 µM) was greater than that of chloroquine (EC50 of 5.47 µM) [157]. In a non-randomized
open-label trial in France, administration of hydroxychloroquine significantly reduced the viral load in
COVID-19 patients, alone or in combination with macrolide antibiotics [158]. However, there are some
limitations to the study including small sample size, unclear criteria for enrollment of cases and controls,
lack of clinical outcomes as well as enrolment of asymptomatic individuals. Widespread administration
of hydroxychloroquine is likely to cause rare adverse effects in patients, including fulminant hepatic
failure, serious cutaneous adverse reactions and ventricular arrhythmias (especially when administrated
with azithromycin) [159]. It has been shown the combination of hydroxychloroquine and azithromycin
in COVID-19 patients is associated with increased risk of QTc prolongation, cardiac dysrhythmias,
and death [160,161]. Additionally, the FDA does not recommend combination therapy of remdesivir
with chloroquine phosphate or hydroxychloroquine sulfate as it might result in a reduced antiviral
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activity of remdesivir [162]. Moreover, the FDA announced the use of hydroxychloroquine and
chloroquine for treatment of hospitalized COVID-19 patients can cause serious heart rhythm problems
and other safety issues, including blood and lymph system disorders, kidney injuries, liver problems
and even liver failure [163]. Owing to the potential side effects—namely heart problems—on June
15th the FDA withdrew the emergency use authorization it issued in March for chloroquine and
hydroxychloroquine as COVID-19 treatments. The FDA made this determination based the results
from the RECOVERY trial in 1542 hospitalized COVID-19 patients administrated hydroxychloroquine,
which found no significant difference in the primary endpoint of 28-day mortality or hospital stay
duration [163,164].
At least 16 different trials for SARS-CoV-2 are already registered in the Chinese clinical
trial registry (http://www.chictr.org.cn) testing the efficacy of chloroquine and hydroxychloroquine.
In addition, hydroxychloroquine is now under evaluation in the U.S. (NCT04308668) as a post-exposure
prophylaxis/preemptive therapy for SARS-CoV-2 infection. Recently the NIH guidelines panel for
COVID-19 treatment recommended against the use of chloroquine or hydroxychloroquine for the
treatment of COVID-19, except in a clinical trial. The panel also recommends against the use of
high-dose chloroquine (600 mg twice daily for 10 days) for the treatment of COVID-19 [165].
8.2.2. Ivermectin
Ivermectin is an FDA-approved broad spectrum anti-parasitic agent mainly used in the treatment
of onchocerciasis, which shows anti-viral effects against HIV-1, simian virus SV40, dengue virus
(DENV), West Nile Virus, Venezuelan equine encephalitis virus (VEEV) and Influenza virus [166].
Ivermectin inhibits the interaction between the integrase protein (IN) of HIV-1 and importin (IMP)
α/β1 heterodimer that is responsible for IN nuclear import [167]. Due to the important role of nuclear
transport of viral proteins in the replication cycle as well as inhibition of the host antiviral response,
targeting this step might be a therapeutic approach [168]. Recently, a study on Vero-hSLAM cell
lines infected with SARS-CoV-2 has shown that ivermectin can reduce viral RNA up to 5000-fold,
equal to a 99.98% reduction after 48 h [166]. Momekov et al. using available pharmacokinetic data from
ivermectin showed that its inhibitory concentrations against the SARS-CoV-2 is unlikely attainable in
humans [169]. Overall, the possible efficacy of ivermectin against SARS-CoV-2 infection needs data to
support it.
9. Immunotherapy
Several studies have been undertaken to develop new treatment strategies for viral infections and
the use of immunotherapy is encouraging [170]. One of the most useful immunotherapy methods
is passive immunity [171], i.e., the transfer of active humoral immunity including ready-made
antibodies. There are two main categories of acquired artificial passive immunity against COVID-19:
treatment with monoclonal antibodies (mAbs) and convalescent plasma from people recovering from
COVID-19 [171]. The antibodies directly bind to the viral antigen and provide an effective anti-viral
response. Several monoclonal antibodies are currently being studied or are undergoing clinical
trials [172].
9.1. Convalescent Plasma Therapy
Convalescent plasma therapy relies on the administration of plasma from recovered COVID-19
patients. Previous coronavirus outbreaks including SARS-CoV and MERS-CoV as well as Ebola
virus disease, avian influenza A (H5N1), 2009 H1N1 pandemic influenza A, respiratory syncytial
virus, Zika viruses, human cytomegalovirus and rabies have confirmed the presence of neutralizing
antibodies in convalescent serum [173,174]. However, convalescent plasma was not successful for
Ebola [175].
Patients with SARS-CoV-2 infection develop a serum antibody response (IgG) to different epitopes of
the virus and some of these antibodies have the potential to neutralize the virus. To prepare convalescent
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plasma, plasma rich in IgG antibody is collected at least two weeks after the recovery date [176].
In SARS-CoV-2, passive antibody therapy mediates protection by virus neutralization and perhaps by
phagocytosis and/or antibody-dependent cellular cytotoxicity [177]. A study by Duan et al. [3] of 10 adult
patients with severe COVID-19 demonstrated that a single dose (200 mL) of convalescent plasma was
not only well tolerated but was able to increase and maintain neutralizing antibodies at a high level.
Moreover, clinical and paraclinical symptoms improved within three days and viral RNA was undetectable
in blood seven days after the transfusion [3]. Passive antibody therapy is more effective as prophylaxis
than for treatment and in infected patients its effectiveness was higher when administered shortly after
the appearance of symptoms [177].
In a Hong Kong study, 80 SARS patients who were administrated convalescent plasma before
day 14 of disease showed an improved prognosis and a higher discharge rate (58.3% vs. 15.6%),
including those who were polymerase chain reaction (PCR) positive and seronegative for SARS-CoV at
the time of therapy [178]. Similarly, transfusion of 500 mL convalescent plasma from three convalescent
SARS patients to three health care workers with SARS infection in Taiwan resulted in survival of all
three patients, a decrease in viral loads to 0 or 1 copy/mL one day after transfusion and increasing
levels of anti-SARS-CoV IgM and IgG [179]. However, administration of convalescent plasma to
three patients with MERS in South Korea showed the presence of neutralizing antibodies in only
two of them [180]. Concerning COVID-19, Zhang et al. demonstrated anti-SARS-CoV-2 activity of
convalescent plasma from six patients in China who had recovered; transfusion of the plasma to a
patient with severe COVID-19 resulted in clinical improvement, with no requirement for mechanical
ventilation 11 days post-plasma transfusion [181]. Similarly, four critically ill COVID-19 patients who
received convalescent plasma and supportive care recovered [104]. The US FDA has approved clinical
trials to test the efficacy and safety of plasma from patients recovering from COVID-19 [182–189],
joining other registered trials in China, Columbia, Iran, Mexico and Baylor Research Institute in
USA [182–189].
9.2. Intravenous Immunoglobulin (IVIG)
IVIG is a supportive therapy prepared from pooled plasma of healthy humans. IVIG is traditionally
used as replacement therapy in patients with humoral immune deficiencies [190]. Unlike convalescent
plasma, IVIG does not contain a SARS-CoV-2 neutralizing antibody [191]. IVIG has various mechanisms
of action including interference with B-cell antigen presentation, immune-modulation and immune
substitution [192]. During the SARS outbreak, IVIG was used as a therapy, but evidence supporting its
effectiveness is inconclusive [193]. Despite some reports on the use of IVIG in MERS infection, there is
not any evidence of anti-MERS activity [194]. As these antibodies are administered intravenously,
they can cause renal failure or thrombosis in MERS patients [195]. For COVID-19, Shi et al. reported
successful treatment of a confirmed patient with advanced respiratory failure, shock and persistent
diarrhea, using intensive plasma exchange (PE) and IVIG transfusion [196]. They emphasized the
importance of early initiation of PE treatment and IVIG to avoid progression to ARDS and multi-organ
failure. Similarly, a multicenter retrospective cohort study of 325 critically unwell adult COVID-19
patients in China who were exposed to IVIG, demonstrated that although early administration
improved their prognosis, mortality at 28-days and 60-days was not improved and total duration of
disease was longer [197]. In a retrospective study of 58 severe or critical COVID-19 patients in Wuhan
treated with IVIG, administration of IVIG within 48 h of admission to ICU improved prognosis by
reducing mechanical ventilation requirement and length of stay [198]. It is important to note that all
of these studies were carried out in the context of small sample size and multiple drug treatments;
thus, the efficacy and the associated adverse effects of IVIG remain unclear. In order to evaluate
the efficacy and safety of IVIG therapy in patients with severe or critical COVID-19, a single-center
randomized, open-label, controlled study has been registered (NCT04261426). Like other proposed
treatments for COVID-19, IVIG is still unlicensed and insufficient evidence exists to support its use in
the management of COVID-19.
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9.3. Monoclonal Antibodies (mAbs)
Monoclonal antibodies are synthesized by one unique parental cell and thus bind to a unique
epitope. To date, several mAbs have been approved by the FDA for viral infections including
SARS-CoV-2 [199]. IL-6 is an attractive target for mAb therapy due to its role in cytokine storm
mediated lung inflammation [200], body temperature regulation and fever. In a study on 20 patients
with COVID-19 in Anhui, China more than 75% of patients admitted to ICU who were given tocilizumab
showed improvement in oxygen saturation and 90% reported resolution of lung opacities on CT
scans, while CRP decreased in 84% [80]. In order to compare the efficiency of tocilizumab and
favipiravir, a randomized controlled trial has been registered in China (ChiCTR2000030894) [201].
Sarilumab (Kevzara) is another IL-6 receptor antagonist (recombinant humanized anti IL-6R monoclonal
antibody) approved for treatment of rheumatoid arthritis [202]. It is currently being evaluated in
a Phase 2/3 clinical trial enrolling hospitalized adult COVID-19 patients, sponsored by Sanofi and
Regeneron Pharmaceuticals (NCT04315298).
Another inflammatory cytokine involved in COVID-19 disease is TNF-α, which can be
targeted by mAbs like adalimumab. Currently, there are several trials registered for assessment
of adalimumab or biosimilar mAbs (Qletli) for their safety and efficacy in COVID-19 treatment in
China (ChiCTR2000030089, ChiCTR2000030580). However, upper respiratory tract infections and
reactivation of hepatitis B infection are common and concerning side effects [203].
Baricitinib is an orally administered, JAK antagonist monoclonal antibody used routinely for the
treatment of rheumatoid arthritis [204]. Although JAK blockers are considered as potential therapeutic
agents in inflammatory storms, several researchers have reported that baricitinib is unlikely to be useful
for COVID-19 [205] due to its well-known side effects, including lymphocytopenia and neutropenia,
and therefore the risk of viral reactivation [205].
Two other potential mAbs are Leronlimab and Ibalizumab, both of which bind specifically
to the C–C chemokine receptor type 5 (CCR5). A phase II clinical trial assessing leronlimab in
COVID-19 patients with respiratory complications was registered in April 2020 [206]. Ibalizumab is
non-immunosuppressive, FDA approved for the treatment of multidrug-resistant HIV in 2018 [207]
and may be considered as a co-treatment agent for COVID-19 in the future.
Camrelizumab is a humanized anti programmed death-1 (PD-1) monoclonal antibody. Blocking PD-1
signaling rescues exhausted CD8+T cells and restores their activity during viral infections, but lung
toxicity is reported [208]. A clinical trial has been registered using camrelizumab for treatment of critical
COVID-19 patients in China [209]. Omalizumab is an IgG1 humanized anti IgE monoclonal antibody that
reduces hypersensitivity to allergens and also decreases late inflammation events, so may be considered
for COVID-19 patients with dermatologic symptoms [210].
Granulocyte-monocyte colony stimulating factor (GM-CSF) is another immunomodulatory
cytokine reported to be present at increased levels in COVID-19 patients [84]. In one clinical trial,
adding a single dose of mAb targeting GM-CSF (mavrilimumab) to standard hospital treatment
improved clinical outcomes in patients with COVID-19 [211].
The mAbs mentioned above were used to modulate the immune response, but specific human
monoclonal antibodies can also be used to neutralize SARS-CoV-2, for both treatment and prevention
of COVID-19. Several neutralizing monoclonal antibodies against SARS-CoV and MERS-CoV have
potential cross reactivity against SARS-CoV-2 [212]. For example, recent studies showed that a
monoclonal antibody (S309) derived from memory B cells from an individual convalescing from
SARS-CoV infection are also capable of neutralizing SARS-CoV-2 [213].
By screening hybridomas from immunized mice using pseudotyped vesicular stomatitis virus,
a chimeric mAb called 47D11 was identified which has cross-neutralizing activity against the S
protein from SARS-CoV and SARS-CoV-2. This antibody was subsequently cloned to produce a fully
humanized mAb, which in cell culture was able to block SARS-CoV-2 infection [214]. In another study,
four mAbs were isolated from individuals who recovered from COVID-19 (B5, B38, H2, and H4),
which were able to neutralize SARS-CoV-2 effectively. In particular, B38 and H4 were able to bind
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Azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) is a widely used macrolide
antibiotic which can inhibit protein synthesis in bacteria by targeting 23S ribosomal RNA. Beside its
antibacterial activity, azithromycin has immunomodulatory and anti-viral effects. Previous studies have
suggested an antiviral function for azithromycin in Ebola virus infection, both in vitro and in mice [216].
Azithromycin (but not other macrolides like erythromycin or telithromycin) can inhibit rhinovirus
replication and release in human bronchial epithelial cells, by inducing expression of interferon and
pro-inflammatory cytokines (IL-6 and IL-8) [217]. Azithromycin also shows dose dependent antiviral
activity against Zika virus in several cell lines (Vero, Hela, A549, Huh7), inhibiting late stages of virus
replication by enhancing the type I and III interferon responses [218]. Interestingly, Tran et al. reported
antiviral activity of azithromycin against Influenza (H1N1) virus; treatment prior to infection inhibited
virus replication by blocking internalization into host cells, without changing viral attachment [219].
Moreover, intranasal administration of azithromycin to infected mice reduced the viral load in affected
lungs [219].
In a non-randomized clinical trial in COVID-19 patients (n = 36), Gautret et al. reported that
azithromycin co-administered with hydroxychloroquine reduced the viral load more efficiently than
hydroxychloroquine alone [158]. Patients were administered hydroxychloroquine (600 mg/day), with or
without azithromycin (500 mg day one, followed by 250 mg/day for four days) and SARS-CoV-2
was measured in nasopharyngeal swabs by quantitative reverse transcriptase PCR (qRT-PCR).
They found that at day 6 all of the patients in the combination group (6/6) were virologically cured
(negative swab), compared to hydroxychloroquine alone (57.1%) or untreated controls (12.5%) [158].
However, this small trial was not randomized, patients were not well matched and adding azithromycin
to hydroxychloroquine may increase the risk of cardiac arrhythmias. There are now several larger clinical
trials investigating the efficacy of azithromycin in COVID-19 patients (e.g., NCT04332107, NCT04336332,
NCT04329832), but until these results are available, Azithromycin cannot be recommended for routine
use in COVID-19.
10.2. Corticosteroids
Corticosteroids are one of the main class of drugs used for chronic inflammatory diseases and
immune disorders. Their anti-inflammatory effects are attributed to activating the transcription of
anti-inflammatory genes and suppressing pro-inflammatory genes through modulation of histone
acetylation [220]. For pneumonia, systemic corticosteroids can be used as an adjuvant to antibiotics,
with an analysis of randomized control studies showing that corticosteroids reduce both mortality and
morbidity in adults with severe community acquired pneumonia [221].
Inflammatory responses of host immune cells and the resulting cytokine storm are two important
aspects of the pathogenesis in severe SARS-CoV-2 infection [222]. However, a meta-analysis of previous
observational studies revealed that corticosteroid therapy is associated with increased mortality (Odds
Ratio OR = 2.12) in patients with influenza [223] and can delay viral clearance in critically ill MERS
patients (adjusted hazard ratio = 0.35) [224]. Another meta-analysis of 15 studies in coronavirus infected
patients (including SARS-CoV, SARS-CoV-2 and MERS-CoV) revealed that while corticosteroids are
likely to be used in critically ill patients, treatment was associated with increased mortality (Risk Ratio
RR = 2.11, p-value = 0.019), increased bacterial infection (RR = 2.08, p < 0.001) and led to longer hospital
stays (total number of patients = 5270) [225]. In an observational study of SARS-CoV-2 infected patients
treated with 40 mg methylprednisolone once or twice daily, there was no significant association between
corticosteroid treatment and time to viral clearance or length of hospitalization [226]. Similarly, Fang et al.
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reported that low-dose methylprednisolone by injection (median hydrocortisone-equivalent dose,
250 mg/day) or orally (median hydrocortisone-equivalent dose = 237.5 mg/day) had no significant
impact on SARS-CoV-2 viral clearance time [227]. Based on these recent results, the World Health
Organization (WHO) has not recommended systemic corticosteroids administration for COVID-19
patients outside of clinical trial studies [228]. Indeed, according to the guidelines for COVID-19 patient
management released by the Center for Disease Control and Prevention (CDC), corticosteroid treatment
is not recommended in confirmed COVID-19 infections except in cases with exacerbation of chronic
obstructive pulmonary disease or septic shock [151].
However, recently the randomized evaluation of COVID-19 therapy (RECOVERY) trial
(NCT04381936) found that dexamethasone (6 milligrams/day for 10 days) can save lives in intubated
COVID-19 patients. Dexamethasone treatment reduced the 28-day mortality by one-third in intubated
patients with invasive ventilation and by one-fifth in cases of patients receiving oxygen; however,
it was not effective for less severe patients who did not required respiratory support [229,230].
Therefore, reflecting its benefit, the NIH COVID-19 treatment guidelines panel recommended
administration of dexamethasone (6 mg/day for up to 10 days) for mechanically ventilated and
oxygen supplemented COVID-19 patients. However, the possible adverse effects of secondary
infections and hypoglycemia should be considered by the treating clinicians [2].
10.3. Nitric Oxide
Nitric Oxide (NO) is a free radical with vasodilator properties. In vascular smooth muscle cells,
NO activates soluble guanylate cyclase resulting in production of cyclic guanosine monophosphate
(cGMP). The latter, acting as a second messenger, activates cGMP-dependent kinase, leading to reduced
cellular calcium level and vasodilation [231]. In vitro studies have reported antiviral activity of the
nitric oxide donor compound S-nitroso-N-acetylpenicillamine for inhibition of SARS-Co-V replication
in Vero E6 cells [232,233]. Nitric oxide inhalation has also been shown to have long term protective
effect (six months after treatment) in ARDS with regard to pulmonary function [234]. Nitric oxide
can inhibit both RNA and protein synthesis of SARS-CoV in vitro [232]. Moreover, nitric oxide or its
derivatives can inhibit palmitoylation of the viral spike protein, affecting virus binding to its receptor
ACE2 and inhibiting SARS-Co-V replication [235]. Nitric oxide inhalation has been successfully used to
treat SARS patients, resulting in elevated oxygen saturation, and reduced or discontinued ventilation
support [236]. There are several clinical trials currently investigating the therapeutic potential of nitric
oxide therapy in patients with COVID-19 (NCT04358588, NCT04305457), as more data are required to
confirm its effectiveness.
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Table 1. List of available drugs targeting SARS-CoV-2 infection and their effective dosage.
Name of Medicine Target Classification Effective Dosage Registered Clinical Trial Reference





Lopinavir/Ritonavir Viral protease Anti-viral
Oral administration 400 mg lopinavir









Favipiravir Viral RdRP Anti-viral
Oral administration 1600 mg twice
daily on first day and 600 mg twice a
day on day 2−14.
2020-001435-27, NCT04359615,
NCT04303299, NCT04402203 [120]
Ribavirin viral RNA Anti-viral
500 mg each time, 2 to 3 times/day in




Arbidol Viral RNA polymerase Anti-viral 200 mg three times a day for aduration of 7–14 days
NCT04260594, NCT04350684,
NCT04255017 [239]
Camostat TMPRSS2 Anti-viral 600 mg (200 mg, three times) NCT04353284 [240]
Nafamostat TMPRSS2 Anti-viral 240 mg daily, for 5 days, peroral NCT04418128 [138]
Chloroquine
Phosphate ACE2 Anti-parasite










IVIG immune modulation Immunoglobulin 400 mg/kg for a duration of five daysin children NCT04411667, NCT04261426 [241]
Ivermectin Inhibition of nucleartransport Anti-parasite
Oral administration 600 µg/kg) daily
for 3 days NCT04343092, NCT04392427 [242]
Tocilizumab IL-6 receptor subunitalpha
Monoclonal
antibody
400 mg intravenous or 8 mg/kg × 1–2
doses. Second dose 8–12 h after first
dose if inadequate response.
NCT04335071, ChiCTR2000030894 [239]
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Table 1. Cont.
Name of Medicine Target Classification Effective Dosage Registered Clinical Trial Reference
Azitromycin 23S rRNA Anti-microbial
500 mg on day 1 followed by














Anti-Inflammation 6 milligrams/day for 10 days ISRCTN50189673, NCT04381936 [243]
Nitricoxide Activates cGMP vasodilator
For SARS patients; Inhalation for
≥3 days (30 ppm on day 1, 20 and
10 ppm on days 2 & 3)
NCT04383002, NCT04338828,
NCT04358588, NCT04305457 [236]
TMPRSS2, transmembrane protease serine 2; ACE2, angiotensin converting enzyme II, IFN-α, interferon-α.
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11. Conclusions and Future Directions
Diverse antiviral drugs with proven activity against influenza virus, SARS or MERS coronaviruses
have been investigated for the treatment of COVID-19, alone or in combination with other drugs
(anti-parasitic agents, anti-inflammatory drugs). Of these, remdesivir has been approved by the FDA
for emergency use in adults and children hospitalized with severe, suspected or laboratory-confirmed
COVID-19. Moreover, the NIH panel recommends remdesivir for treatment of COVID-19 in
patients who are on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) [2].
Dexamethasone treatment showed promising results in reducing the 28-day mortality in intubated
patients and in cases receiving oxygen. The WHO reported that it could be lifesaving for critically
ill COVID-19 patients and the NIH panel recommends using dexamethasone at proven doses in
COVID-19 patients who are mechanically ventilated, as well as in patients who require supplemental
oxygen but are not mechanically ventilated [2].
Early data on administration of hydroxychloroquine often in combination with azithromycin were
promising, however studies were very low quality, with methodological concerns raised including
small subject numbers, poor study design, the absence of appropriate controls and end points of unclear
utility. Therefore, on 4 July 2020 the WHO accepted the recommendation from the Solidarity Trial’s
International Steering Committee to discontinue the hydroxychloroquine arm in the trial. The fusion
inhibitor umifenovir and protease inhibitor lopinavir /ritonavir were also regarded initially as likely
effective candidates to treat COVID-19. However, the NIH panel now recommends against the use
of chloroquine, hydroxychloroquine, Lopinavir/ritonavir or non-SARS-CoV-2-specific intravenous
immune globulin (IVIG) for the treatment of COVID-19, except in a clinical trial. Furthermore,
NIH does not recommend either for or against the use of COVID-19 convalescent plasma, SARS-CoV-2
immune globulin or Interleukin-6 inhibitors (e.g., sarilumab, siltuximab, tocilizumab) for the treatment
of COVID-19, due to insufficient data.
The constantly changing recommendations from major international health bodies highlights
the challenges of treating a novel deadly pathogen in the midst of a rapidly escalating pandemic.
However, it also reinforces the importance of undertaking large, well designed clinical trials to evaluate
potential treatments, instead of relying on preliminary unpublished data or the latest rumors on social
media. The widespread empiric use of unproven agents such as hydroxychloroquine can lead to
supply shortages for people who rely on the drug, potentially life-threatening side effects, and delays
in evaluating its true clinical efficacy, along with that of other potential therapies. Many large trials are
now underway to assess both novel and repurposed drugs to treat COVID-19, and their outcomes are
eagerly awaited. Given the scale of the pandemic even incremental improvements can save thousands
of lives, while we await the development of potent antiviral agents, targeted immunotherapies or an
effective vaccine.
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COVID-19 Coronavirus disease 2019
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
FDA US Food and Drug Administration
MERS-CoV Middle East respiratory syndrome coronavirus
ARDS acute respiratory distress syndrome
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RSCU synonymous codon usage
NSP non-structural proteins





RBD receptor binding domain
ACE2 angiotensin converting enzyme II
Cryo-EM cryo-electron microscopy
HAT human airway trypsin-like protease
ssRNA single stranded RNA




RdRp RNA-dependent RNA polymerases
ER endoplasmic reticulum
TI IF type I interferons
IFN-α interferon-α
Bcl-xL B-cell lymphoma-extra large
PAMPs pathogen associated molecular patterns
TLR toll-like receptors
IRF3 IFN regulatory factor 3
IL interleukin
TNF tumor necrosis factor
RLRs RIG-I-like receptors
CLRs C-type lectin-like receptors
NLR NOD-like receptor
APCs antigen presenting cells
MHC major histocompatibility complex
HLA human leukocyte antigen
CTLs cytotoxic T lymphocytes
CD cluster of differentiation
DCs dendritic cells
MCP-1 monocyte chemoattractant protein-1
CRS), cytokine release syndrome
CRP C-reactive protein
sIL-6R IL-6 receptor
JAK-STAT3 Janus kinase-signal transducer and activator of transcription 3
Tregs regulatory T cells
RDV Remdesivir
EC50 half-maximal effective concentration
CC50 half-cytotoxic concentration
LPV/r Lopinavir/Ritonavir
HIV-1 human immunodeficiency virus-1
ESICM The European Society of Intensive Care Medicine
SCCM The Society of Critical Care Medicine
NIH The National Institutes of Health
FPV Favipiravir
ARB Arbidol
HCV hepatitis B virus, hepatitis C virus
HA hemagglutinin
HCoV-NL63 human coronavirus NL63
DENV dengue virus
VEEV Venezuelan equine encephalitis virus




ERGIC ER–Golgi intermediate compartment
IVIG intravenous immunoglobulin
PE plasma exchange
ICU intensive care unit
PCR polymerase chain reaction
qRT-PCR quantitative reverse transcriptase PCR
WHO World Health Organization
PD-1 programmed death-1
CDC left for disease control and prevention
NO nitric oxide
cGMP cyclic guanosine monophosphate
GM-CSF granulocyte-monocyte stimulating factor
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